Literature DB >> 31691261

Orbital diseases mimicking graves' orbitopathy: a long-standing challenge in differential diagnosis.

M Marinò1, I Ionni2, G Lanzolla2, A Sframeli3, F Latrofa2, R Rocchi2, C Marcocci2.   

Abstract

Graves' orbitopathy (GO) is the most common cause of orbital tissue inflammation, accounting for ~ 60% of all orbital inflammatory conditions in the population aged 21-60 years, and for ~ 40% in the population aged > 60 year. GO is observed in 25-30% of patients with Graves' hyperthyroidism and more rarely in association with hypothyroid autoimmune thyroiditis. In addition, a small proportion of GO patients (1-2%) do not have a clinically overt thyroid dysfunction. Clinically, GO is characterized by proptosis, inflammation involving the eyelids and the conjunctiva, extraocular muscle hypertrophy, with consequent reduction of ocular motility and diplopia, and in the most severe cases, compression of the optic nerves at the orbital apex, with reduction of visual acuity. At CT scan or MRI, a muscle increase involving the superior, medial and inferior rectus is quite typical. In the most severe forms, compression of the optic nerves at the orbital apex can be observed. Euthyroid GO is usually an early sign of a full-blown Graves' disease; however, in some cases, the orbital disease can remain isolated. Moreover, euthyroid GO can rarely be unilateral, which makes the picture even more confusing. Under those circumstances, the diagnostic process becomes obviously quite difficult, having other conditions mimicking GO been excluded. A number of inflammatory conditions affecting orbital tissue can mimic GO, thereby requiring an accurate evaluation for a proper differential diagnosis. The majority of these conditions are immune mediated. Most of them are benign, but they can be rather aggressive and some can cause visual loss. The most common inflammatory condition affecting orbital tissues and mimicking GO is idiopathic orbital inflammation. Other, more rare, orbital diseases that should be considered in the differential diagnosis are infections, orbital manifestations of systemic diseases, primitive and secondary orbital neoplasms, and orbital vascular alterations. In most instances, when an orbitopathy occurs in the absence of hyperthyroidism, the diagnosis of the disease underlying the ocular symptoms and signs is based on exclusion of the other conditions. Here we review the conditions that can mimic GO and how to distinguish them from this obnoxious eye disease.

Entities:  

Keywords:  Graves’ disease; Graves’ orbitopathy; Idiopathic orbital inflammation; Orbital lymphoma; Pseudotumor

Mesh:

Year:  2019        PMID: 31691261     DOI: 10.1007/s40618-019-01141-3

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   5.467


  44 in total

Review 1.  Insulin-like Growth Factor-I Receptor and Thyroid-Associated Ophthalmopathy.

Authors:  Terry J Smith; Joseph A M J L Janssen
Journal:  Endocr Rev       Date:  2019-02-01       Impact factor: 19.871

2.  Role of the underlying thyroid disease on the phenotype of Graves' orbitopathy in a tertiary referral center.

Authors:  Marenza Leo; Francesca Menconi; Roberto Rocchi; Francesco Latrofa; Eleonora Sisti; Maria Antonietta Profilo; Barbara Mazzi; Eleonora Albano; Marco Nardi; Paolo Vitti; Claudio Marcocci; Michele Marinò
Journal:  Thyroid       Date:  2015-02-11       Impact factor: 6.568

3.  Antioxidant Actions of Selenium in Orbital Fibroblasts: A Basis for the Effects of Selenium in Graves' Orbitopathy.

Authors:  Giovanna Rotondo Dottore; Marenza Leo; Giamberto Casini; Francesco Latrofa; Luca Cestari; Stefano Sellari-Franceschini; Marco Nardi; Paolo Vitti; Claudio Marcocci; Michele Marinò
Journal:  Thyroid       Date:  2016-12-16       Impact factor: 6.568

4.  Antioxidant effects of β-carotene, but not of retinol and vitamin E, in orbital fibroblasts from patients with Graves' orbitopathy (GO).

Authors:  G Rotondo Dottore; I Ionni; F Menconi; G Casini; S Sellari-Franceschini; M Nardi; P Vitti; C Marcocci; M Marinò
Journal:  J Endocrinol Invest       Date:  2017-12-18       Impact factor: 4.256

5.  Action of three bioavailable antioxidants in orbital fibroblasts from patients with Graves' orbitopathy (GO): a new frontier for GO treatment?

Authors:  G Rotondo Dottore; I Ionni; F Menconi; G Casini; S Sellari-Franceschini; M Nardi; P Vitti; C Marcocci; M Marinò
Journal:  J Endocrinol Invest       Date:  2017-06-27       Impact factor: 4.256

Review 6.  Prevalence and natural history of Graves' orbitopathy in the XXI century.

Authors:  E Piantanida; M L Tanda; A Lai; L Sassi; L Bartalena
Journal:  J Endocrinol Invest       Date:  2013-04-16       Impact factor: 4.256

7.  The 2016 European Thyroid Association/European Group on Graves' Orbitopathy Guidelines for the Management of Graves' Orbitopathy.

Authors:  Luigi Bartalena; Lelio Baldeschi; Kostas Boboridis; Anja Eckstein; George J Kahaly; Claudio Marcocci; Petros Perros; Mario Salvi; Wilmar M Wiersinga
Journal:  Eur Thyroid J       Date:  2016-03-02

Review 8.  Current Insights into the Pathogenesis of Graves' Ophthalmopathy.

Authors:  R S Bahn
Journal:  Horm Metab Res       Date:  2015-09-11       Impact factor: 2.936

9.  Association of T and B Cells Infiltrating Orbital Tissues With Clinical Features of Graves Orbitopathy.

Authors:  Giovanna Rotondo Dottore; Liborio Torregrossa; Patrizio Caturegli; Ilaria Ionni; Angela Sframeli; Elena Sabini; Francesca Menconi; Paolo Piaggi; Stefano Sellari-Franceschini; Marco Nardi; Francesco Latrofa; Paolo Vitti; Claudio Marcocci; Fulvio Basolo; Michele Marinò
Journal:  JAMA Ophthalmol       Date:  2018-06-01       Impact factor: 7.389

10.  A Case of Unilateral Dermopathy Possibly Related to Graves' Disease.

Authors:  Cosimo Rodia; Francesca Menconi; Laura Mazoni; Liborio Torregrossa; Fulvio Basolo; Paolo Vitti; Claudio Marcocci; Michele Marinò
Journal:  Eur Thyroid J       Date:  2019-06-11
View more
  11 in total

1.  Analysis of the Application Value of Ultrasound Three-Dimensional Speckle Tracking Technology Combined with Thyroid Autoantibodies and Hormones in the Diagnosis and Treatment of Graves' Disease.

Authors:  Yi Xu; Songxia Peng; Li Qin; Dianjing Sun; Jianlin Geng; Qingqing Liu
Journal:  Evid Based Complement Alternat Med       Date:  2022-07-06       Impact factor: 2.650

2.  Sensitivity of three thyrotropin receptor antibody assays in thyroid-associated orbitopathy.

Authors:  Marija Sarić-Matutinović; Tanja Diana; Biljana Nedeljković-Beleslin; Jasmina Ćirić; Miloš Žarković; Iva Perović-Blagojević; George J Kahaly; Svetlana Ignjatović
Journal:  J Med Biochem       Date:  2022-04-08       Impact factor: 2.157

Review 3.  Stimulatory Thyrotropin Receptor Antibodies Are a Biomarker for Graves' Orbitopathy.

Authors:  Augustine George; Tanja Diana; Jan Längericht; George J Kahaly
Journal:  Front Endocrinol (Lausanne)       Date:  2021-02-02       Impact factor: 5.555

4.  Case Report: Orbital Myositis and Myasthenia Gravis as Symptoms of Immune Reconstitution Inflammatory Syndrome in a Patient With Human Immunodeficiency Virus Infection.

Authors:  Yanli Wang; Ning Zhao; Jun Yang; Ying Wen
Journal:  Front Immunol       Date:  2020-12-14       Impact factor: 7.561

Review 5.  Epidemiology, Natural History, Risk Factors, and Prevention of Graves' Orbitopathy.

Authors:  Luigi Bartalena; Eliana Piantanida; Daniela Gallo; Adriana Lai; Maria Laura Tanda
Journal:  Front Endocrinol (Lausanne)       Date:  2020-11-30       Impact factor: 5.555

6.  Identification of tRNA-Related Fragments and Their Potential Regulatory Effects in Thyroid-Associated Ophthalmopathy.

Authors:  Zifan Yue; Fei Tong; Chengcheng Zeng; Ruili Wei
Journal:  Front Genet       Date:  2022-04-04       Impact factor: 4.772

Review 7.  Sarcoid Uveitis: An Intriguing Challenger.

Authors:  Pia Allegri; Sara Olivari; Federico Rissotto; Roberta Rissotto
Journal:  Medicina (Kaunas)       Date:  2022-07-04       Impact factor: 2.948

8.  Proteotranscriptomics of ocular adnexal B-cell lymphoma reveals an oncogenic role of alternative splicing and identifies a diagnostic marker.

Authors:  Jiahao Shi; Tianyu Zhu; Huimin Lin; Zhen Liu; Min Zhou; Ziyao Yu; Xiaowen Zhou; Xin Song; Yefei Wang; Renbing Jia; Xianqun Fan; Yixiong Zhou
Journal:  J Exp Clin Cancer Res       Date:  2022-07-30

9.  Clinical value of functional thyrotropin receptor antibodies in Serbian patients with Graves' orbitopathy.

Authors:  G J Kahaly; S Ignjatović; M Sarić Matutinović; T Diana; B Nedeljković Beleslin; J Ćirić; M Žarković
Journal:  J Endocrinol Invest       Date:  2021-07-29       Impact factor: 4.256

Review 10.  Thyrotropin receptor antibodies and Graves' orbitopathy.

Authors:  T Diana; K A Ponto; G J Kahaly
Journal:  J Endocrinol Invest       Date:  2020-08-04       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.